Today's Daily Dose brings you news about Atossa's progress in phase I study of its proprietary topical Endoxifen in men; the three biopharmaceutical companies that are set to debut on the Nasdaq on June 21, 2018; Kindred Biosciences' financial position; FDA panel review date of Paratek's Omadacycline NDA, and STAAR Surgical's resolution of FDA warning letter.